Page 1646 - Williams Hematology ( PDFDrive )

1620 Part XI: Malignant Lymphoid Diseases Chapter 97: Hodgkin Lymphoma 1621

140. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP- 168. Wongso D, Fuchs M, Plutschow A, et al: Treatment-related mortality in patients with
resistant Hodgkin’s disease. Ann Intern Med 96:139–143, 1982. advanced-stage Hodgkin lymphoma: An analysis of the German Hodgkin Study
141. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and Group. J Clin Oncol 31:2819–2824, 2013.
MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: Report of an 169. Federico M, Luminari S, Iannitto E, et al: ABVD compared with BEACOPP compared
intergroup trial. J Clin Oncol 21:607–614, 2003. with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma:
142. Canellos GP, Niedzwiecki D, Johnson JL: Long-term follow-up of survival in Hodgkin’s Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol
lymphoma. N Engl J Med 361:2390–2391, 2009. 27:805–811, 2009.
143. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP 170. Viviani S, Zinzani PL, Rambaldi A, et al: ABVD versus BEACOPP for Hodgkin’s lym-
chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J phoma when high-dose salvage is planned. N Engl J Med 365:203–212, 2011.
Med 348:2386–2395, 2003. 171. Carde P, Karrasch M, Fortpied C, et al: BEACOPP (escalated × 4 + baseline × 4 cycles)
144. Engert A, Diehl V, Franklin J, et al: Escalated-dose BEACOPP in the treatment of vs ABVD (×8 cycles) in stage III-IV, high risk Hodgkin lymphoma (IPS >3). Intergroup
patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG Study 20012 (Abstract 8002). J Clin Oncol 30:510s, 2012.
HD9 study. J Clin Oncol 27:4548–4554, 2009. 172. Borchmann P, Haverkamp H, Diehl V, et al: Eight cycles of escalated-dose BEACOPP
145. Armitage JO: Early-stage Hodgkin’s lymphoma. N Engl J Med 363:653–662, 2010. compared with four cycles of escalated-dose BEACOPP followed by four cycles of
146. Horning SJ, Hoppe RT, Hancock SL, et al: Vinblastine, bleomycin, and methotrexate: baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage
An effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol 6:1822–1831, 1988. Hodgkin’s lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study
147. Ferme C, Eghbali H, Meerwaldt JH, et al: Chemotherapy plus involved-field radiation Group. J Clin Oncol 29:4234–4242, 2011.
in early-stage Hodgkin’s disease. N Engl J Med 357:1916–1927, 2007. 173. Engert A, Haverkamp H, Kobe C, et al: Reduced-intensity chemotherapy and PET-
148. Press OW, LeBlanc M, Lichter AS, et al: Phase III randomized intergroup trial of subto- guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15
tal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradi- trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791–1799,
ation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 19:4238–4244, 2001. 2012.
149. Bonadonna G, Bonfante V, Viviani S, et al: ABVD plus subtotal nodal versus involved- 174. Gallamini A, Kostakoglu L: Interim FDG-PET in Hodgkin lymphoma: A compass for a
field radiotherapy in early-stage Hodgkin’s disease: Long-term results. J Clin Oncol safe navigation in clinical trials? Blood 120:4913–4920, 2012.
22:2835–2841, 2004. 175. Kostakoglu L, Gallamini A: Interim 18F-FDG PET in Hodgkin lymphoma: Would
150. Engert A, Schiller P, Josting A, et al: Involved-field radiotherapy is equally effective and PET-adapted clinical trials lead to a paradigm shift? J Nucl Med 54:1082–1093,
less toxic compared with extended-field radiotherapy after four cycles of chemotherapy 2013.
in patients with early-stage unfavorable Hodgkin’s lymphoma: Results of the HD8 trial 176. Kobe C, Dietlein M, Franklin J, et al: Positron emission tomography has a high negative
of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608, 2003. predictive value for progression or early relapse for patients with residual disease after
151. Behringer K, Borchmann P, Diehl V, et al: Impact of bleomycin and dacarbazine within first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989–3994,
the ABVD regimen in the treatment of early stage favorable Hodgkin lymphoma: Final 2008.
results of the GHSG HD13 trial (abstract T033). Haematologica 98(Suppl 2):11, 2013. 177. Markova J, Kobe C, Skopalova M, et al: FDG-PET for assessment of early treatment
152. Moskowitz CS, Chou JF, Wolden SL, et al: Breast cancer after chest radiation therapy for response after four cycles of chemotherapy in patients with advanced-stage Hodgkin’s
childhood cancer. J Clin Oncol 32:2217–2223, 2014. lymphoma has a high negative predictive value. Ann Oncol 20:1270–1274, 2009.
153. Canellos GP, Abramson JS, Fisher DC, et al: Treatment of favorable, limited-stage 178. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive
Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. and advanced Hodgkin’s disease: Mature results of a prospective clinical trial. J Clin
J Clin Oncol 28:1611–1615, 2010. Oncol 20:630–637, 2002.
154. Straus DJ, Portlock CS, Qin J, et al: Results of a prospective randomized clinical trial of 179. Chisesi T, Federico M, Levis A, et al: ABVD versus Stanford V versus MEC in unfa-
doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation vourable Hodgkin’s lymphoma: Results of a randomised trial. Ann Oncol 13 Suppl
therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. 1:102–106, 2002.
Blood 104:3483–3489, 2004. 180. Hoskin PJ, Lowry L, Horwich A, et al: Randomized comparison of the Stanford V regi-
155. Meyer RM, Gospodarowicz MK, Connors JM, et al: ABVD alone versus radiation-based men and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom
therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366:399–408, 2012. National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin
156. Noordijk EM, Thomas J, Ferme C: First results of the EORTC-GELA H9 randomized Oncol 27:5390–5396, 2009.
trials: The H9-F trial and H9u trial in patients with favorable or unfavorable early stage 181. Gordon LI, Hong F, Fisher RI, et al: Randomized phase III trial of ABVD versus
Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 23:6505a, 2005. Stanford V with or without radiation therapy in locally extensive and advanced-stage
157. Herbst C, Rehan FA, Skoetz N, et al: Chemotherapy alone versus chemotherapy plus radio- Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative
therapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2:CD007110, 2011. Oncology Group (E2496). J Clin Oncol 31:684–691, 2013.
158. Hoppe RT, Advani RH, Ai WZ, et al: NCCN Clinical Practice Guidelines in Oncology 182. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed
(NCCN Guidelines) Hodgkin lymphoma V.2.2014: National Comprehensive Cancer CD30-positive lymphomas. N Engl J Med 363:1812–1821, 2010.
Network, 2014. Available at NCCN.org. http://www.nccn.org/professionals/physician_ 183. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuxi-
gls/pdf/hodgkins.pdf. Last Accessed on August 25, 2015. mab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol
159. Eich HT, Diehl V, Gorgen H, et al: Intensified chemotherapy and dose-reduced involved- 30:2183–2189, 2012.
field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: Final analysis of 184. Younes A, Connors JM, Park SI, et al: Brentuximab vedotin combined with ABVD or
the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199–4206, 2010. AVD for patients with newly diagnosed Hodgkin’s lymphoma: A phase 1, open-label,
160. Borchmann P, Engert A, Pluetschow A: Dose-intensified combined modality treatment dose-escalation study. Lancet Oncol 14:1348–1356, 2013.
with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field 185. Aleman BM, Raemaekers JM, Tirelli U, et al: Involved-field radiotherapy for advanced
radiotherapy (IF-RT) is superior to 4 cycles of ABVD and IFRT in patients with early Hodgkin’s lymphoma. N Engl J Med 348:2396–2406, 2003.
unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study 186. Gianni AM, Rambaldi A, Zinzani P: Comparable 3-year outcome following ABVD or
Group (GHSG) HD14 trial. ASH Annu Meet Abstr 112:367, 2008. BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced
161. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin’s Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL
disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: cooperative groups. J Clin Oncol 26: Abstract 8506, 2008.
1478–1484, 1992. 187. Nogova L, Reineke T, Eich HT, et al: Extended field radiotherapy, combined modal-
162. Canellos GP, Niedzwiecki D: Long-term follow-up of Hodgkin’s disease trial. N Engl J ity treatment or involved field radiotherapy for patients with stage IA lymphocyte-
Med 346:1417–1418, 2002. predominant Hodgkin’s lymphoma: A retrospective analysis from the German
163. Connors JM, Klimo P, Adams G, et al: Treatment of advanced Hodgkin’s disease with Hodgkin Study Group (GHSG). Ann Oncol 16:1683–1687, 2005.
chemotherapy—comparison of MOPP/ABV hybrid regimen with alternating courses 188. Fanale M: Lymphocyte-predominant Hodgkin lymphoma: What is the optimal treat-
of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical ment? Hematology Am Soc Hematol Educ Program 2013:406–413, 2013.
trials group. J Clin Oncol 15:1638–1645, 1997. 189. Schulz H, Rehwald U, Morschhauser F, et al: Rituximab in relapsed lymphocyte-
164. Viviani S, Bonadonna G, Santoro A, et al: Alternating versus hybrid MOPP and ABVD predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German
combinations in advanced Hodgkin’s disease: Ten-year results. J Clin Oncol 14:1421– Hodgkin Lymphoma Study Group (GHSG). Blood 111:109–111, 2008.
1430, 1996. 190. Advani RH, Horning SJ, Hoppe RT, et al: Mature results of a phase II study of rituxi-
165. Eichenauer DA, Thielen I, Haverkamp H, et al: Therapy-related acute myeloid leukemia mab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol
and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from 32:912–918, 2014.
the German Hodgkin Study Group. Blood 123:1658–1664, 2014. 191. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous
166. Behringer K, Mueller H, Goergen H, et al: Gonadal function and fertility in survivors bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: Results of a
after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 BNLI randomised trial. Lancet 341:1051–1054, 1993.
to HD15 trials. J Clin Oncol 31:231–239, 2013. 192. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy com-
167. Sieniawski M, Reineke T, Nogova L, et al: Fertility in male patients with advanced pared with high-dose chemotherapy with autologous haemopoietic stem-cell trans-
Hodgkin lymphoma treated with BEACOPP: A report of the German Hodgkin Study plantation for relapsed chemosensitive Hodgkin’s disease: A randomised trial. Lancet
Group (GHSG). Blood 111:71–76, 2008. 359:2065–2071, 2002.

Kaushansky_chapter 97_p1603-1624.indd 1621 9/18/15 11:12 PM